

DEFLAZACORT TABLETS PRESCRIPTION FORM

Fax: 877.765.6254 | **Phone:** 800.605.1524

| 1 - PATIENT INFORMATION | | | | | | |
|--|---|---------------------------|-------------------|---------------|------|--------|
| ☑ Please attach demographic information. | | | | | | |
| Patient Name (First, MI, Last): | | | DOB: | Gender: | Male | Female |
| Address: | | City: | | State:_ | Zip: | |
| Patient Phone Number: | | _ | | | | |
| Parent/Caregiver Name (First, MI, Last): | | Paren | t/Caregiver Phone | Number: | | |
| 2 – INSURANCE INFORMATION | | | | | | |
| ☑ Please attach front and back of patient's insurance card, | , prescription car | d, and/or Medicaid | card. | | | |
| Primary Insurance Name: | | Secondary Insurance Name: | | | | |
| Primary Insurance ID: | | Secondary Insu | urance ID: | | | |
| Insurance Phone Number: | | Insurance Pho | ne Number: | | | |
| Policyholder Name: | | Policyholder Na | ame: | | | |
| 3 – CLINICAL INFORMATION | | | | | | |
| Please fax clinical documentation to pharmacy along with | th referral form. | | | | | |
| ICD-10 Diagnosis Code: G71.01 Duchenne Muscula NKDA Drug Allergies: | | | Code: | | | |
| Patient Weight: lb kg D | ate Weight Obta | nined: | Date of Last | Clinic Visit: | | |
| 4 - PRESCRIBER INFORMATION | | | | | | |
| Practice Name: | | | | | | |
| Prescriber Name: | | | | NPI: | | |
| Address: | | | | | | |
| Office Contact: | Phone: | | | Fax: | | |
| 5 - PRESCRIPTION INFORMATION | | | | | | |
| Upsher-Smith Deflazacort Tablets (Recommended do | se: 0.9 mg/kg/ | day) | | | | |
| Tablet strength: Check one option | strength: Check one option Directions for use: Check one option | | | | | |
| DEFLAZACORT Tablets 6 mg NDC 0832-0814-11 | Take 0.9 mg/kg orally once daily | | | | | |
| DEFLAZACORT Tablets 18 mg NDC 0832-0815-30 | Takemg orally once daily | | | | | |
| DEFLAZACORT Tablets 30 mg NDC 0832-0816-30 | Other Directions: | | | | | |
| DEFLAZACORT Tablets 36 mg NDC 0832-0817-30 | Dispense: 30 Day Supply Refills: 1 year | | | | | |
| Prescriber's Signature: Physician attests this is his/ho | er signature. | | | | | |
| X | | | | | | |
| DAW Signature* / Date | | | | | | |
| X | | | | | | |
| Substitution Permitted / Date | | | | | | |

*Certain states require "brand medically necessary" or other language to be handwritten by the prescriber if he/she has made this determination in his/her independent clinical judgment. **Note:** The prescriber should comply with state-specific prescription requirements. Noncompliance could result in outreach to the prescriber. All Program terms and conditions apply. Other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by the express authority of the sender to the named addressee.